TCTMD2h
Acoramidis Approved in Europe for ATTR Cardiomyopathy
Nearly 3 months after the FDA green-lit the TTR stabilizer, it joins tafamidis as the second therapy in Europe for the ...
BridgeBio price target raised to $49 from $48 at Scotiabank
Scotiabank analyst Greg Harrison raised the firm’s price target on BridgeBio (BBIO) to $49 from $48 and keeps an Outperform rating on the ...
BridgeBio shares rise on Scotiabank price target boost
Shares of BridgeBio Pharma (NASDAQ:BBIO), currently valued at $5.88 billion, witnessed an uptick as Scotiabank (TSX:BNS) analyst Greg Harrison increased the price target to $49 from $48 while ...
pharmaphorum7h
BridgeBio gets EU nod for ATTR cardiomyopathy drug
The EU is the second market for the drug after the US, where it was approved under the Attruby brand name last November, on ...
EC grants marketing authorisation to BridgeBio’s ATTR-CM treatment
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.BoQAct6R.js ...
PipelineReview.com12h
BEYONTTRA™ (acoramidis), the First Near Complete TTR Stabilizer (≥90%), Approved by the European Commission to Treat ATTR-CM
PALO ALTO, CA, USA I February 11, 2025 I BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused ...